Re: Farmas USA
RDUS +20%
Fco mejor que el de AMGN
• Radius Health (NASDAQ:RDUS) is up 20% premarket on increased volume in reaction to Amgen's announcement of Phase 3 data for its osteoporosis candidate romosozumab that showed a 73% reduction in the risk of vertebral fracture in postmenopausal women.
• Radius' candidate, abaloparatide, showed an 83% reduction in vertebral fracture in its Phase 3 ACTIVE study. Its marketing application is currently under review in Europe. It expects to file its NDA in the U.S. in the near future.